HBV
  • Featured content
    Led by Tram T. Tran, MD, a panel of experts discusses their approach to individualizing initial HCV therapy based on key disease and patient characteristics that have an impact on treatment choice, including HCV genotype, race, cirrhosis, comorbidities, and comedications.
  • Featured content
    In this CME-certified video module, Leonard H. Calabrese, DO; Robert P. Perrillo, MD, FAASLD; and Andrew D. Zelenetz, MD, PhD, discuss best practices in HBV screening and prophylaxis for patients who will undergo immunosuppressive therapy.
  • Featured content
    In this CME-certified video module, Leonard H. Calabrese, DO; Robert P. Perrillo, MD, FAASLD; and Andrew D. Zelenetz, MD, PhD, discuss best practices in HBV screening and prophylaxis for patients who will undergo immunosuppressive therapy.
  • Featured content
    In this CME-certified video module, Leonard H. Calabrese, DO; Robert P. Perrillo, MD, FAASLD; and Andrew D. Zelenetz, MD, PhD, discuss best practices in HBV screening and prophylaxis for patients who will undergo immunosuppressive therapy.
  • Featured content
    In this downloadable slideset, Leonard H. Calabrese, DO; Robert P. Perrillo, MD, FAASLD; and Andrew D. Zelenetz, MD, PhD, review HBV reactivation risk, screening, and prophylaxis for patients who will undergo immunosuppressive therapy.
    Date Posted: 10/18/2016
  • 1
  • 2
  • 3
  • 4
  • 5

Latest Content

10 of 42 Shown
10 of 42 Shown
Show 10 More
Loading...